A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

Recruiting

Phase 1

HBI-2438A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

Sponsor:

HUYABIO International, LLC.

Code:

NCT05485974

Conditions

Lung Cancer

Non Small Cell Lung Cancer

Colorectal Cancer

Cancer of Pancreas

Colon Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

HBI-2438

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by HUYABIO International, LLC. on 2023-09-13.